Possible use of adaptation to hypoxia in Alzheimer's disease: A hypothesis

Medical Science Monitor

Volumn 11, Issue 8, 2005, Pages

  Malyshev, Igor Yu ^a   Wiegant, Frederik A C ^b   Mashina, Svetlana Yu ^a   Torshin, Vladimir I ^c   Goryacheva, Anna V ^a   Khomenko, Inna P ^a   Kruglov, Sergey V ^a   Pokidyshev, Dmitry A ^a   Popkova, Elena V ^a   Pshennikova, Maya G ^a   Vlasova, Mariya A ^a   Zelenina, Olga M ^a   Manukhina, Eugenia B ^a  

^a INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^b UTRECHT UNIVERSITY   (Netherlands)

^c PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

Author keywords

Adaptation to hypoxia; Alzheimer's disease; Cerebral circulation; Heat shock proteins; Nitric oxide; Oxidative stress

Indexed keywords

AMYLOID BETA PROTEIN; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; CORTICOSTERONE; FREE RADICAL; GINKGO BILOBA EXTRACT; GLUTAMATE RECEPTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIC FACTOR; NITRIC OXIDE;

ADAPTATION; ALZHEIMER DISEASE; BRAIN BLOOD VESSEL; BRAIN CIRCULATION; CALCIUM HOMEOSTASIS; HUMAN; HYPOXIA; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; OXIDATIVE STRESS; PATHOGENESIS; QUALITY OF LIFE; REVIEW; WELLBEING;

ADAPTATION, PHYSIOLOGICAL; ALZHEIMER DISEASE; ANIMALS; ANOXIA; CEREBROVASCULAR CIRCULATION; ENVIRONMENT; FREE RADICALS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MODELS, BIOLOGICAL; NITRIC OXIDE; OXIDATION-REDUCTION;

EID: 24044440942     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Katzman R, Kawas C: The epidemiology of dementia and Alzheimer's disease. In: Terry R, Katzman R, Bick KL (eds). Alzheimer disease. New York, Raven Press, 1994
2. Clippingdale AB, Wade JD, Barrow CJ: The amyloid-beta peptide and its role in Alzheimer's disease. J Pept Sci, 2001; 7: 227-29
3. Christen Y: Oxidative stress and Alzheimer disease. Am J Clin Nutr, 2000; 71: 621S-29S
4. Dodd PR: Excited to death: different ways to lose your neurons. Biogerontology, 2002; 3: 51-56
5. Hu J, Akama KT, Krafft GA et al: Amyloid-beta peptide activates cultured astrosytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res, 1998; 785: 195-206
6. Sasaki A, Yamaguchi H, Ogawa A et al: Microglial activation in early stages of amyloid beta protein deposition. Acta Neuropathol (Berl.), 1997; 94: 316-22
7. Ohtsuka K, Suzuki T: Roles of molecular chaperones in the nervous system. Brain Res Bull, 2000; 53: 141-46
8. Kubes P, Kanwar S, Niu XF: Nitric oxide synthesis inhibition induces leukocyte adhesion via superoxide and must cells. FASEB J, 1993; 7: 1293-99
9. Mueller XM, Tevaearai H, Chaubert P et al: Mechanism of action of transmyocardial revascularization. Schweiz Med Wochenschr, 1999; 129: 1889-92
10. Monte de la SM, Lu BX, Sohn YK et al: Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neurodegeneration. Neurobiol Aging, 2000; 21: 309-19
11. Torre de la JC, Stefano GB: Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res Rev, 2000; 34: 119-36
12. McDonnell J, Redekop WK, van der Roer N et al: The cost of treatment of Alzheimer's disease in The Netherlands: a regression-based simulation model. Pharmacoeconomics, 2001; 19: 379-90
13. Berghmans RL: Anti-Alzheimer drugs: ethical aspects of research and practice. Tijdschr Gerontol Geriatr, 2000; 31: 100-6
14. Bachurin SO: Medical chemistry of targeted search for drugs for treatment and prevention of neurodegenerative diseases as exemplified by Alzheimer's disease. In: Neurodegenerative diseases and aging. Zavalishin IA, Yakhno NN, Gavrilova SI, (eds). Moscow, 2001; 399-454 (in Russian)
15. Malyshev IYu, Manukhina EB: Stress, adaptation and nitric oxide. In: Adaptation biology and medicine (Vol. 2). Pandolf BB, Takeda N, Singal PK (eds). New Delhi, Narosa Publ House, 1999; 375-92
16. Manukhina EB, Malyshev IYu: Stress-limiting system of nitric oxide. Rossijskij Fiziologicheskij Zhurnal, 2000; 86: 1283-92 (in Russian)
17. Meerson FZ: Adaptation, stress and prophylaxis, Berlin, Springer-Verlag, 1984
18. Ball LJ, Birge SJ: Prevention of brain aging and dementia. Clin Geriatr Med, 2002; 18: 485-503
19. Heininger K: A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. Rev Neurosci, 2000; 11: 213-328
20. Ahlemeyer B, Krieglstein J: Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease. Pharmacopsychiatry, 2003; 36(Suppl.1): S8-S14
21. Mook-Jung I, Kim H, Fan W et al: Neuroprotective effects of constituents of the Oriental Crude Drugs, Rhodiola sacra, R. sachalinensis and Tokaku-joki-to against Beta-amyloid toxicity, oxidative stress and apoptosis. Biol Pharm Bull, 2002; 25: 1101-4
22. Mattson MP: Neuroprotective signaling and the aging brain: take away my food and let me run. Brain Res, 2000; 886: 47-53
23. Mattson MP, Duan W, Chan SL et al: Neuroprotective and neurorestorative signal transduction mechanisms in brain aging: modification by genes, diet and behavior. Neurobiol of Aging, 2002; 23: 695-705
24. Addae JI, Youssef FF, Stone TW: Neuroprotective role of learning in dementia: a biological explanation. J Alzheimer's Dis, 2003; 5: 91-104
25. Mahendra N, Arkin S: Effects of four years of exercise, language, and social interventions on Alzheimer discourse. J Commun Disord, 2003; 36: 395-422
26. Teri L, Gibbons LE, McCurry SM et al: Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA, 2003; 290: 2015-22
27. Laurin D, Verreault R, Lindsay J et al: Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol, 2001; 58: 498-504
28. Meerson FZ: Essentials of adaptive medicine: Protective effects of adaptation. Moscow, Hypoxia Medical, LTD, 1994
29. Abraham I, Harkany T, Horvath KM et al: Chronic corticosterone administration dose-dependently modulates Abeta(1-42)- and NMDA-induced neurodegeneration in rat magnocellular nucleus basalis. J Neuroendocrinol, 2000; 12: 486-94
30. Swaab DF, Dubelaar EJ, Scherder EJ et al: Therapeutic strategies for Alzheimer disease: focus on neuronal reactivation of metabolically impaired neurons. Alzheimer Dis Assoc Disord, 2003; 17: S114-22
31. Meerson FZ, Pinelis VG, Koshelev VB et al: Adaptation to periodic hypoxia restricts subdural hemorrhages in audiogenic epileptiform convulsions in rats. Biull Eksp Biol Med, 1993; 116: 572-74
32. Gulyaeva NV, Stepanichev MV, Onifriev MV et al: Interval hypoxia training prevents oxidative stress in striatum and locomotor disturbances in a rat model of parkinsonism. In: Progress in Alzheimer's and Parkinson's diseases. Fisher A, Hanln I, Yoshida M (eds). New York, Plenum Press, 1998; 717-23
33. Zee van der EA, Douma BR, Bohus B, Luiten PG: Passive avoidance training induces enhanced levels of immunoreactivity for muscarinic acetylcholine receptor and coexpressed PKC gamma and MAP-2 in rat cortical neurons. Cereb Cortex, 1994; 4: 376-90
34. Rayevsky KS, Bondarenko NA Kudrin VS, Miroshnichenko II: Cognitive deficiency induced by the acute stress in rats: a possible role of brain catecholaminergic systems. Ann Ist Super Sanita, 1990; 26: 25-29
35. Manukhina EB, Mashina SYu, Pokidyshev DA et al: Role of nitric oxide overproduction and deficiency in Alzheimer's disease. In: Endothelial Dysfunction: Experimental and Clinical Studies. Sidorenko GI, Solodkov AP, Shebeko VI, Rodionov YuYa. Vitebsk, VGMU, 2004; 15-25 (in Russian)
36. Meerson FZ, Arkhipenko IV, Rozhitskaia II et al: Opposite effects on antioxidant enzymes of adaptation to continuous and intermittent hypoxia. Biull Eksp Biol Med, 1992; 114: 14-15 (in Russian)
37. Pshennikova MG, Manukhina EB, Sazontova TG et al: Molecular mechanisms of adaptation to environmental factors: New achievements of the Meerson school. In: Adaptation biology and medicine (Vol. 2). Pandolf BB, Takeda N, Singal PK (eds). New Delhi, Narosa Publ. House, 1999; 199-213
38. Manukhina EB, Mashina SYu, Smirin BV, Lyamina NP et al: Role of nitric oxide in adaptation to hypoxia and adaptive defense. Physiol Res, 2000; 49: 89-97
39. Grundman M, Grundman M, Delaney P: Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc, 2002; 61: 191-202
40. El'chaninova SA, Koreniak NA, Smagina IV et al: Intermittent hypoxia in the treatment of dyscirculatory encephalopathy. Zh Nevrol Psikhiatr Im SS Korsakova, 2002; 102: 29-32 (in Russian)
41. Cardinali DP, Brusco LI, Liberczuk C, Furio AM: The use of melatonin in Alzheimer's disease. Neuroendocrinol Lett Suppl, 2002; 1: 20-23
42. Reiter RJ, Cabrera J, Sainz RM et al: Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism. Ann NY Acad Sci, 1999; 890: 471-85
43. Pappolla MA, Sos M, Omar RA, Sambamurti K: The heat shock/oxidative stress connection. Relevance to Alzheimer disease. Mol Chem Neuropathol, 1996; 28: 21-34
44. Kaur C, Srinivasan KN, Singh J et al: Plasma melatonin, pinealocyte morphology, and surface receptors/antigen expression on macrophages/microglia in the pineal gland following a high-altitude exposure. J Neurosci Res, 2002; 67: 533-43
45. Charbrier P-E, Demerlé-Pallardy C, Auguet M: Nitric oxide synthases: targets for therapeutic strategies in neurological diseases. Cell Mol Life Sci, 1999; 55: 1029-35
46. McCarty MF: Vascular nitric oxide may lessen Alzheimer's risk. Med Hypotheses, 1998; 51: 465-76
47. Ghosh C, Lahiri DK: Increased vulnerability of neuronal cell lines to sodium nitroprusside-mediated toxicity is caused by the decreased level of nitric oxide metabolites. J Mol Neurosci, 1999; 13: 77-92
48. Tarkowski E, Ringqvist A, Blennow K et al: Intrathecal release of nitric oxide in Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord, 2000; 11: 322-26
49. Malyshev IYu, Malugin AV, Golubeva LYu et al: Nitric oxide donor induces HSP70 accumulation in the heart and in cultured cells. FEBS Lett, 1996; 391: 21-23
50. Malyshev IYu, Manukhina EB, Mikoyan VD et al: Nitric oxide is involved in heat-induced HSP70 accumulation. FEBS Lett, 1995; 370: 159-62
51. Willis D, Tomlinson A, Frederick R, Paul-Clark MJ: Modulation of heme oxygenase activity and rat brain and spleen by inhibitors and donors of nitric oxide. Biochem Biophys Res Commun, 1995; 214: 1152-56
52. Takahashi K, Hara E, Suzuki H et al: Expression of heme oxygenase isozyme mRNAs in the human brains and induction of heme oxygenase-1 by nitric oxide donors. J Neurochem, 1996; 67: 482-89
53. Cellermajer DS: Endothelial dysfunction: Does it matter? Is it reversible? J Am Coll Cardiol, 1997; 30: 325-53
54. Manukhina EB, Malyshev IYu: Role of nitric oxide in protective effects of adaptation. Adaptation Biology and Medicine (Vol. 3). Moravec J, Takeda N, Singal PK (eds). New Delhi, Narosa Publishing House, 2002; 312-27
55. Sessa WC, Pritchard K, Seyedi N et al: Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res, 1994; 74: 349-53
56. Hampl V, Cornfield DN, Cowan NJ, Archer SL: Hypoxia potentiates nitric oxide synthesis and transiently increases cytosolic calcium level in pulmonary artery endothelial cells. Eur Resp J, 1995; 8: 515-22
57. Assreuy J, Cunha FQ, Liew FY, Moncada S: Feedback inhibition of nitric oxide synthase activity by nitric oxide. Br J Pharmacol, 1993; 108: 833-37
58. Manukhina EB, Smirin BV, Malyshev IYu et al: Nitric oxide stores in the cardiovascular system. Izvestiya AN, 2002; 5: 585-96 (in Russian)
59. Lederman RJ, Mendelson FO, Anderson RD et al: Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial. Lancet, 2002; 359: 2948-50
60. Pecher P, Schumacher BA: Angiogenesis in ischemic human myocardium: clinical results after 3 years. Ann Thorac Surg, 2000; 69: 1414-19
61. Losordo DW, Vale PR, Symes JF et al: Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of ph-VEGF165 as sole therapy for myocardial ischemia. Circulation, 1998; 98: 2800-4
62. Wissink MJ, Beernink R, Poot AA et al: Improved endothelization of vascular grafts by local release of growth factors from heparinized collagen matrices. J Controlled Release, 2000; 64: 103-14
63. Boyer M, Townsen LE, Vogel L et al: Isolation of endothelial cells from human peripheral blood. J Vasc Surg, 2000; 31: 181-89
64. Prewitt RL, Cardoso SS, Wood WB: Prevention of arteriolar rarefaction in the spontaneously hypertensive rat by exposure to simulated high altitude. J Hypertens, 1986; 4: 735-40
65. Zamudio S: The placenta at high altitude. High Alt Med Biol, 2003; 4: 171-91
66. Manukhina EB, Sokolova IA, Rodionov IM: Changed density of the vascular network on brain surface in rats with experimental hypertension and adaptation to high altitude. Kardiologia, 1982; 10: 118-19 (in Russian)
67. Wenger RH, Gassmann M: Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem, 1997; 378: 609-16
68. Brown IR, Gozes I: Stress genes in the nervous system during development and aging diseases. Ann NY Acad Sci, 1998; 851: 123-28
69. Wakutani Y, Urakami K, Shimomura T, Takahashi K: Heat shock protein 70 mRNA levels in mononuclear blood cells from patients with dementia of the Alzheimer type. Dementia, 1995; 6: 301-5
70. Getchell TV, Krishna NS, Dhooper N et al: Human olfactory receptor neurons express heat shock protein 70: age-related trends. Ann Otol Rhinol Laryngol, 1995; 104: 47-50
71. Klein SD, Brune B: Heat-shock protein 70 attenuates nitric oxide-induced apoptosis in RAW macrophages by preventing cytochrome c release. Biochem J, 2002; 362(Pt 3): 635-41
72. Ravagnan L, Gurbuxani S, Susin SA et al: Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat Cell Biol, 2001; 3: 839-43
73. Gabai VL, Meriin AB, Yaglom JA et al: Role of Hsp70 in regulation of stress-kinase JNK: implications in apoptosis and aging. FEBS Lett, 1998; 438: 1-4
74. Yoo CG, Lee S, Lee CT et al: Anti-inflammatory effect of heat shock protein induction is related to stabilization of I kappa B alpha through preventing I kappa B kinase activation in respiratory epithelial cells. J Immunol, 2000; 164: 5416-23
75. Kudva YC, Hiddinga HJ, Butler PC et al: Small heat shock proteins inhibit in vitro Abeta(1-42) amyloidogenesis. FEBS Lett, 1997; 416: 117-21
76. Kakimura J, Kitamura Y, Takata K et al: Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J, 2002; 16: 601-3
77. Johnson G, Refolo LM, Wallace W: Heat-shocked neuronal PC12 cells reveal Alzheimer's disease - associated alterations in amyloid precursor protein and tau. Ann NY Acad Sci, 1993; 695: 194-97
78. Kirby BA, Merril CR, Ghanbari H, Wallace WC: Heat shock proteins protect against stress-related phosphorylation of tau in neuronal PC12 cells that have acquired thermotolerance. J Neurosci, 1994; 14: 5687-93
79. Yee WM, Frim DM, Isacson O: Relationships between stress protein induction and NMDA-mediated neuronal death in the entorhinal cortex Exp Brain Res, 1993; 94: 193-202
80. Yan SD, Fu J, Soto C et al: An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature, 1997; 389: 689-95
81. D'Andrea MR, Nagele RG, Wang HY et al: Evidence that neurons accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology, 2001; 38: 120-34
82. Fonte V, Kapulkin V, Taft A et al: Interaction of intracellular β amyloid peptide with chaperone proteins. Proc Natl Acad Sci USA, 2002; 99: 9439-44
83. Omata N, Murata T, Takamatsu S et al: Hypoxic tolerance induction in rat brain slices following hypoxic preconditioning due to expression of neuroprotective proteins as revealed by dynamic changes in glucose metabolism. Neurosci Lett, 2002; 329: 205-8
84. Papadopoulos MC, Sun XY, Cao J et al: Over-expression of HSP-70 protects astrocytes from combined oxygen-glucose deprivation. Neuroreport, 1996; 7: 429-32
85. Malyshev IYu, Zenina TA, Golubeva LYu et al: NO-dependent mechanisms of adaptation to hypoxia. Nitric Oxide, 1999; 3: 105-13